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will be located in patient accessible areas around the unit to ensure
anonymity. Based upon admission rates, it is anticipated that data
collection will be complete by December. Descriptive statistics will
be used to evaluate items on the OPPQNCS, return rates will be
calculated, and staff will be polled as to any difﬁculty approaching
patients.
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MULTIDISCIPLINARY CLINICAL INITIATIVES TO DECREASE THE RISK
OF ETHICAL DILEMMAS
Neumann, J.L., Trevino, C., Hosing, C., Champlin, R. The University
of Texas MD Anderson Cancer Center, Houston, TX
Blood and Marrow Transplantation (BMT) healthcare providers
are confronted by a number of clinical situations that may chal-
lenge their technical skills, intellect, as well as beliefs, values and
principles. Having a professional responsibility to advocate for
patients, practitioners may have to come to terms with competing
ethical principles presented by differences in resources allocation,
religious beliefs, and societal mores. BMT care is unique in that
patients present with a life threatening illness, if untreated. In
addition, many of the interventions for control or cure tend to be
very aggressive and can greatly impact the individual’s quality of
life. The uncertainty related to the treatment options and out-
comes may also lead to difﬁculty in decisions making and potential
ethical dilemmas.
The purpose of this poster or presentation will be to identify
clinical initiatives, which have been successful in preventing or
resolving ethical dilemmas challenging the patient/family and the
healthcare team. These ethical issues include: advanced level of
appropriate care; informed consent; do not resusciate; and discon-
tinuation of medically inappropriate care. Clinical initiatives that
are currently being utilized include: ethics rounds; informal ethics
consult; advanced directive taskforce; care conferences; self-care
and caregiver agreements; and creation of a compliance algorithm/
pathway. Results of nurse survey examining the impact of ethics
rounds will be presented, as well as information about institutional
ethics consults. Copies of self-care and caregiver agreements and
educational material about advanced directives for high risk pa-
tients will be provided.
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HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM DISTRESS IN
PATIENTS UNDERGOING NON-MYELOABLATIVE (NST) VERSUS MY-
ELOABLATIVE (MT) ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION (PBSCT)
Bevans, M.1, Marden, S.1, Leidy, N.2, Soeken, K.3, Rivera, P.1, Cusack,
G.1, Mayberry, H.1, Bishop, M.4, Barrett, J.5 1. National Institues of
Health, Bethesda, MD; 2. MEDTAP International, Bethesda, MD; 3.
University of Maryland, Baltimore, MD; 4. National Cancer Institute,
Bethesda, MD; 5. National Heart, Lung, and Blood Institute, Bethesda,
MD
We prospectively examined health-related quality of life
(HRQL) and symptom distress (SD) in adult patients with hema-
tologic diseases undergoing PBSCT from HLA-identical sibling
donors receiving a ﬂudarabine/cyclophosphamide (CY) regimen
NST with unmanipulated cells (n  40), or a CY-total body
irradiation regimen MT with T-cell depletion (n  36). Generic
HRQL was measured by the physical (PCS) and mental (MCS)
summary scores of the Medical Outcomes Study Short Form-36
(SF-36). The Functional Assessment of Cancer Therapy-General
(FACT-G) and Bone Marrow Transplant (FACT-BMT; FACT-
G  BMT subscale) total scores were used to measure condition-
and treatment-speciﬁc HRQL, respectively. Higher scores indicate
better HRQL. SD was measured by the Symptom Distress Scale
(SDS). Higher scores indicate a greater level of SD. Subjects
completed surveys pre-treatment (FACT-G; SF-36; SDS) and on
days 0 (FACT-BMT; SDS), 30 and 100 (FACT-BMT; SF-36;
SDS). To compare HRQL (FACT-BMT, PCS, MCS) between
MT and NST, mixed linear modeling was used taking into account
the correlation between repeated measurements within subjects
over time. Due to group baseline demographic and clinical differ-
ences, baseline PCS and FACT-G served as covariates in the
respective models. To examine the relationship between SD and
HRQL at days 30 and 100, an exploratory analysis was conducted
using multiple regression with age, gender, ethnicity, group, and
disease status also included as predictors. Subjects (N  76) were
mostly male (67%), had ECOG status 0 or 1 (97%), and were in
remission or with stable disease (65%). HRQL scores showed no
difference between groups across time and no effect for group.
HRQL improved signiﬁcantly (p  0.05) in both groups over time
with higher scores at day 100 versus days 0 and 30. At days 30 and
100, SD had the highest beta weight contributing signiﬁcantly (p
0 .001) to the variance of HRQL scores and those with lower SD
scores had higher HRQL scores (Table). For the set of predictors,
the variance explained in HRQL ranged from 43% to 72% (Ta-
ble). Results suggest NST and MT have a similar effect on HRQL
during the ﬁrst 100 days post-transplant, despite the greater inten-
sity of the MT conditioning regimen. Lower SD is associated with
better HRQL and is an important contributor to its prediction
during the ﬁrst 100 days following allogeneic PBSCT.
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UNIQUE ANTI-EMETIC MANAGEMENT IN THE PEDIATRIC BONE MAR-
ROW TRANSPLANT PATIENTS
Smith, A., Smith, C., Youssef, S., Andrews, L., Olson, E., Gonzalez-
Ryan, L. Children’s Healthcare of Atlanta, AFLAC Cancer Center,
Atlanta, GA
Bone marrow transplantation (BMT) requires a stringent prepar-
ative regimen that results in a multitude of adverse effects. One of
the most distressing effects for these patients is chemotherapy-
induced nausea and vomiting (CINV). BMT patients require close
monitoring and thorough assessments, especially when suffering a
stressful side effect. Nurses should be knowledgeable of all possible
anti-emetic therapies. Routine anti-emetics include 5-HT3 recep-
tor antagonist, dopamine receptor antagonist, benzodiazepine, an-
ti-histamine and steroid. Different combinations of the above-
mentioned medications have been used in preventing or
controlling CINV and have been effective in majority of the time.
However, there are situations that patients will suffer from persis-
tent CINV. We described a unique experience in our pediatric
BMT patients in whom a combination of diphenhydramine
(Benadryl), lorazepam (Ativan), and dexamethasone (Decadron)
(BAD) was administered (modiﬁed from Dix SP et al, Bone Mar-
row Transplant, 1999). Patients received this mixture as a contin-
uous infusion and with patient-controlled boluses for persistent
CINV control. A total of 10 patients received the BAD drip during
the BMT course. Even with the continuous infusion, the accumu-
lated daily amount of each medication patient received was actually
lower than the total dose when each medication was given at
scheduled intervals. All patients experienced improved CINV
Table. Signiﬁcant Predictors of HRQL at Days 30 and 100
FACT-BMT PCS MCS
Beta Beta Beta
Day 30
Symptom distress .74† .61† .53†
Treatment group
(1  MT; 2 
NST) .22* — —
Gender (female) — .21* .28*
R2 (adj.R2) .61 (.56) .50 (.44) .43 (.36)
Day 100
Symptom distress .76† .55† .44†
Ethnicity (white) .32* — —
Age — .44† —
R2 (adj.R2) .72 (.67) .47 (.39) .46 (.37)
*P  .05; †P  .001.
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